410 related articles for article (PubMed ID: 22327313)
1. Antiangiogenic therapy for advanced renal cell carcinoma: management of treatment-related toxicities.
Cohen RB; Oudard S
Invest New Drugs; 2012 Oct; 30(5):2066-79. PubMed ID: 22327313
[TBL] [Abstract][Full Text] [Related]
2. Toxicities of targeted agents in advanced renal cell carcinoma.
Patel P; Srinivas S
Curr Clin Pharmacol; 2011 Aug; 6(3):181-8. PubMed ID: 21827392
[TBL] [Abstract][Full Text] [Related]
3. Anti-angiogenic targets in the treatment of advanced renal cell carcinoma.
Heng DY; Bukowski RM
Curr Cancer Drug Targets; 2008 Dec; 8(8):676-82. PubMed ID: 19075590
[TBL] [Abstract][Full Text] [Related]
4. Targeted therapy for advanced renal cell cancer (RCC): a Cochrane systematic review of published randomised trials.
Coppin C; Kollmannsberger C; Le L; Porzsolt F; Wilt TJ
BJU Int; 2011 Nov; 108(10):1556-63. PubMed ID: 21952069
[TBL] [Abstract][Full Text] [Related]
5. Optimal management of metastatic renal cell carcinoma: current status.
Escudier B; Albiges L; Sonpavde G
Drugs; 2013 Apr; 73(5):427-38. PubMed ID: 23572408
[TBL] [Abstract][Full Text] [Related]
6. [Novelties in the treatment for advanced renal-cell cancer].
Maráz A
Orv Hetil; 2011 Apr; 152(17):655-62. PubMed ID: 21464023
[TBL] [Abstract][Full Text] [Related]
7. Impact of anti-angiogenic treatments on metastatic renal cell carcinoma.
Ainsworth NL; Lee JS; Eisen T
Expert Rev Anticancer Ther; 2009 Dec; 9(12):1793-805. PubMed ID: 19954291
[TBL] [Abstract][Full Text] [Related]
8. Evolving role of novel targeted agents in renal cell carcinoma.
Hutson TE; Figlin RA
Oncology (Williston Park); 2007 Sep; 21(10):1175-80; discussion 1184, 1187, 1190. PubMed ID: 17926797
[TBL] [Abstract][Full Text] [Related]
9. Dosing strategies and optimization of targeted therapy in advanced renal cell carcinoma.
Ryan CW
J Oncol Pharm Pract; 2017 Jan; 23(1):43-55. PubMed ID: 26625878
[TBL] [Abstract][Full Text] [Related]
10. Antiangiogenic treatments and mechanisms of action in renal cell carcinoma.
Négrier S; Raymond E
Invest New Drugs; 2012 Aug; 30(4):1791-801. PubMed ID: 21573959
[TBL] [Abstract][Full Text] [Related]
11. Improvement in survival end points of patients with metastatic renal cell carcinoma through sequential targeted therapy.
Calvo E; Schmidinger M; Heng DY; Grünwald V; Escudier B
Cancer Treat Rev; 2016 Nov; 50():109-117. PubMed ID: 27664394
[TBL] [Abstract][Full Text] [Related]
12. Treatment patterns in metastatic renal cell carcinoma: a retrospective review of medical records from US community oncology practices.
Jonasch E; Signorovitch JE; Lin PL; Liu Z; Culver K; Pal SK; Scott JA; Vogelzang NJ
Curr Med Res Opin; 2014 Oct; 30(10):2041-50. PubMed ID: 24983741
[TBL] [Abstract][Full Text] [Related]
13. Sequential targeted therapy after pazopanib therapy in patients with metastatic renal cell cancer: efficacy and toxicity.
Bellmunt J; Pons F; Foreshew A; Fay AP; Powles T; Porta C; Bracarda S; Lampron ME; Cerbone L; Sternberg CN; Hutson TE; Choueiri TK
Clin Genitourin Cancer; 2014 Aug; 12(4):262-9. PubMed ID: 24795159
[TBL] [Abstract][Full Text] [Related]
14. Activity of single-agent bevacizumab in patients with metastatic renal cell carcinoma previously treated with vascular endothelial growth factor tyrosine kinase inhibitors.
Turnbull JD; Cobert J; Jaffe T; Harrison MR; George DJ; Armstrong AJ
Clin Genitourin Cancer; 2013 Mar; 11(1):45-50. PubMed ID: 23041453
[TBL] [Abstract][Full Text] [Related]
15. Targeted therapy for renal cell cancer: current perspectives.
van der Veldt AA; Haanen JB; van den Eertwegh AJ; Boven E
Discov Med; 2010 Nov; 10(54):394-405. PubMed ID: 21122471
[TBL] [Abstract][Full Text] [Related]
16. Tubulocystic renal cell carcinoma: is there a rational reason for targeted therapy using angiogenic inhibition? Analysis of seven cases.
Steiner P; Hora M; Stehlik J; Martinek P; Vanecek T; Petersson F; Michal M; Korabecna M; Travnicek I; Hes O
Virchows Arch; 2013 Feb; 462(2):183-92. PubMed ID: 23296808
[TBL] [Abstract][Full Text] [Related]
17. Targeted therapies in the treatment of advanced renal cell carcinoma.
Seront E; Machiels JP
Recent Pat Anticancer Drug Discov; 2009 Jun; 4(2):146-56. PubMed ID: 19519537
[TBL] [Abstract][Full Text] [Related]
18. Treatment-associated adverse event management in the advanced renal cell carcinoma patient treated with targeted therapies.
Ravaud A
Oncologist; 2011; 16 Suppl 2(Suppl 2):32-44. PubMed ID: 21346038
[TBL] [Abstract][Full Text] [Related]
19. [Angiogenesis and renal cell carcinoma].
Billemont B; Méric JB; Izzedine H; Taillade L; Sultan-Amar V; Rixe O
Bull Cancer; 2007 Jul; 94 Spec No():S232-40. PubMed ID: 17846009
[TBL] [Abstract][Full Text] [Related]
20. Vascular endothelial growth factor-targeted therapies in advanced renal cell carcinoma.
Albiges L; Salem M; Rini B; Escudier B
Hematol Oncol Clin North Am; 2011 Aug; 25(4):813-33. PubMed ID: 21763969
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]